Investago | logo
Investago
Investago
Investago | Pfizer's New Patient Portal Initiative
Time to read: 1 minutes
Pfizer's New Patient Portal Initiative

Pfizer has announced its entry into the direct-to-consumer business, a significant shift that mirrors a similar move by Eli Lilly earlier this year. Pfizer's new platform, PfizerForAll, is designed to streamline the process for patients seeking treatments for migraines, respiratory viruses, and vaccines. The initiative is part of Pfizer's broader strategy to enhance patient access to its products by simplifying the often complicated and time-consuming healthcare system.

Aamir Malik, Pfizer's Chief US Commercial Officer, emphasized that the platform aims to reduce the frustrations patients often face when navigating the healthcare system. Patients frequently struggle to find doctors who can promptly write the necessary prescriptions, and they also encounter various insurance hurdles, such as pre-authorization requirements and finding pharmacies that offer medications at lower co-pay costs. PfizerForAll seeks to address these issues by offering an alternative pathway for patients to access the medications they need.

 

 

However, Pfizer is clear that the platform will not force patients to choose Pfizer products; instead, the decision remains with the clinicians. The platform will also include a customer helpline to assist patients with common issues, such as dealing with insurers to remove access barriers.

 

 

Pfizer will drive traffic to the portal through targeted social media campaigns, guiding patients to specific landing pages based on their health concerns. From there, patients can opt for a telehealth visit through UpScript for $35 or an in-person visit via ZocDoc. The platform is not a replacement for the current healthcare system but rather an additional resource to enhance access and introduce patients to new treatment options.

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 88.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Investago
Test your knowledge
Are you curious about your trading level? Now it's time for you to take this trading quiz questions. In the quiz you will find a few questions which are designed that you will have a better understanding of trading after. We wish you best luck!
Related news
Investago
18. August 2024
Lam Research: A Strategic Buy Amid Market Volatility

Lam Research (LRCX), a key player in the semiconductor manufacturing equipment industry, has seen its stock decline nearly 30% during the recent tech sell-off.* Despite this drop, the company remains a st...

Read more
Investago
30. July 2024
Evaluating JPMorgan’s Investment Potential

JPMorgan Chase (NYSE: JPM) has delivered a remarkable total return of 365% over the past decade, outperforming the S&P 500. As of July 25, its market cap reached $599 billion. The bank posted strong Q...

Read more
Investago
19. June 2024
Disney's Growth Potential - Buy Now?

The Walt Disney Company (NYSE: DIS) has encountered a challenging three years, with rising costs, waning interest in theatrical films, the ongoing decline of cable TV, and an activist investor's influence...

Read more
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 88.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.